Aurora Fires Back as Curaleaf Seeks to Halt Its ATM Program
ACB sits 49% above its 52-week low of $2.56 on light trading volume (0.3× avg).
Summary
Aurora Cannabis responded to Curaleaf's application to halt its ATM program, calling it a distraction from the inadequate hostile bid. Aurora revealed its own regulatory complaint against Curaleaf and disclosed the ATM has been inactive for weeks.
Key Events · M&A and Partnerships · ACB
-
Curaleaf Seeks ATM Halt
Curaleaf filed an application to halt Aurora's at-the-market equity program, which Aurora characterizes as a distraction from the hostile bid's inadequacy.
-
Aurora Files ASC Complaint
Aurora filed a complaint with the Alberta Securities Commission on September 2 regarding deficiencies in Curaleaf's hostile bid, which Curaleaf has not addressed.
-
ATM Program Status Disclosed
Aurora states the ATM was publicly announced in February 2026, has been inactive for several weeks, and was not utilized for three years prior to February 2026.
-
Board Reaffirms Rejection
Aurora's Special Committee and Board unanimously recommend shareholders reject Curaleaf's US$4.00 per share bid by taking no action and not tendering shares.
Analysis · ACB · Life Sciences
The hostile takeover battle between Aurora Cannabis and Curaleaf escalated on September 14 when Curaleaf filed an application to halt Aurora's at-the-market equity program. Aurora's response reveals two new regulatory fronts: Curaleaf's ATM-halt application and Aurora's own September 2 complaint to the Alberta Securities Commission about deficiencies in Curaleaf's bid. Aurora also disclosed that its ATM has been inactive for several weeks and was unused for three years prior to February 2026 — a direct rebuttal to Curaleaf's claim that the ATM was a defensive maneuver. The filing reinforces Aurora's unanimous board recommendation to reject the US$4.00 per share bid, which Aurora maintains significantly undervalues the company.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $248M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.